News
![IMV Inc. to Present at Two Upcoming Investor Events: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
IMV Inc. to Present at Two Upcoming Investor Events
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers today
![Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeThpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d91333dbb55b274fa0400e435af0453aa80c824/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aurinia-logo-web-700px.jpg?locale=us)
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.
-
H.C. Wainwright
![IMV Appoints Andrew Hall as Chief Executive Officer: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
IMV Appoints Andrew Hall as Chief Executive Officer
IMV Inc. (NASDAQ: IMV; TSX: IMV), (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and
![IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today
![IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, today
![Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeThpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d91333dbb55b274fa0400e435af0453aa80c824/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aurinia-logo-web-700px.jpg?locale=us)
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced
![Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and blood cancers, today announced
![IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers while preserving
![EnWave Signs Royalty-Bearing Commercial License Agreement and Equipment Purchase Agreement with Nippon Trends Food Services, Inc.](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
EnWave Signs Royalty-Bearing Commercial License Agreement and Equipment Purchase Agreement with Nippon Trends Food Services, Inc.
Vancouver, B.C., December 1, 2020. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced
![EnWave unterzeichnet kostenpflichtige kommerzielle Lizenzvereinbarung und Ausrüstungskaufvertrag mit Nippon Trends Food Services, Inc.](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
EnWave unterzeichnet kostenpflichtige kommerzielle Lizenzvereinbarung und Ausrüstungskaufvertrag mit Nippon Trends Food Services, Inc.
Vancouver, B.C., 1. Dezember 2020. Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
![EnWave unterzeichnet zweiten Anlagenkaufvertrag mit Patata Torres um die REV™ Fertigungskapazität um 100kW zu erhöhen](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
EnWave unterzeichnet zweiten Anlagenkaufvertrag mit Patata Torres um die REV™ Fertigungskapazität um 100kW zu erhöhen
Vancouver, B.C., 30. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
![EnWave Signs Second Equipment Purchase Agreement with Patata Torres to Increase REV™ Manufacturing Capacity by 100kW](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EnWave Signs Second Equipment Purchase Agreement with Patata Torres to Increase REV™ Manufacturing Capacity by 100kW
Vancouver, B.C., November 30, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
![EnWave Signs Royalty-Bearing Commercial License and Receives Deposit for 70kW of REV™ Machinery from NuWave Foods for the Production of Shelf-Stable Baked Goods](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EnWave Signs Royalty-Bearing Commercial License and Receives Deposit for 70kW of REV™ Machinery from NuWave Foods for the Production of Shelf-Stable Baked Goods
Vancouver, B.C., November 23, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
![EnWave unterzeichnet lizenzgebührenpflichtige kommerzielle Lizenz und erhält eine Anzahlung für 70kW REV™ Anlage von NuWave Foods für die Herstellung von haltbaren Backwaren](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EnWave unterzeichnet lizenzgebührenpflichtige kommerzielle Lizenz und erhält eine Anzahlung für 70kW REV™ Anlage von NuWave Foods für die Herstellung von haltbaren Backwaren
Vancouver, B.C., 23. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
![EnWave Appoints Mr. Pablo Cussatti to its Board of Directors, Announces Retirement of Director, Mr. Hugh McKinnon](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EnWave Appoints Mr. Pablo Cussatti to its Board of Directors, Announces Retirement of Director, Mr. Hugh McKinnon
Vancouver, B.C., November 20, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/), announced today
![EnWave beruft Pablo Cussatti in den Verwaltungsrat und kündigt Rücktritt des Direktors Hugh McKinnon an](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EnWave beruft Pablo Cussatti in den Verwaltungsrat und kündigt Rücktritt des Direktors Hugh McKinnon an
Vancouver, B.C., 20. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
![EnWave Sells EU-GMP 10kW REV™ Machine to Pharmaceutical Cannabis Cultivator in Europe](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
EnWave Sells EU-GMP 10kW REV™ Machine to Pharmaceutical Cannabis Cultivator in Europe
Vancouver, B.C., June 29, 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today
![EnWave verkauft EU-GMP 10kW REV™ Maschine an Pharmazeutischen Cannabiszüchter in Europa](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
EnWave verkauft EU-GMP 10kW REV™ Maschine an Pharmazeutischen Cannabiszüchter in Europa
Vancouver, B.C., 29. Juni 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab heute
![EnWave verkauft 10kW Maschine an Fungaria Snack Ltd. für Obst- und Gemüseproduktion in Ungarn](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EnWave verkauft 10kW Maschine an Fungaria Snack Ltd. für Obst- und Gemüseproduktion in Ungarn
Vancouver, B.C., 28. Juni 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
![EnWave Sells 10kW Machine to Fungaria Snack Ltd. for Fruit and Vegetable Production in Hungary](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EnWave Sells 10kW Machine to Fungaria Snack Ltd. for Fruit and Vegetable Production in Hungary
Vancouver, B.C., June 28, 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today
![EnWave verkauft dritte 10-kW-REV™-Maschine an Dairy Concepts IRL und erhöht damit weiter die Kapazität für die Produktion von lagerstabilen Molkereisnacks](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
EnWave verkauft dritte 10-kW-REV™-Maschine an Dairy Concepts IRL und erhöht damit weiter die Kapazität für die Produktion von lagerstabilen Molkereisnacks
Vancouver, B.C., 27. Juni 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) ("EnWave") gab bekannt, dass Dairy Concepts IRL ("DCI"), ein aufstrebender Marktführer im Bereich innovativer
![EnWave Sells Third 10kW REV™ Machine to Dairy Concepts IRL, Further Increasing Capacity for Shelf-Stable Dairy Snack Production](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
EnWave Sells Third 10kW REV™ Machine to Dairy Concepts IRL, Further Increasing Capacity for Shelf-Stable Dairy Snack Production
Vancouver, B.C., June 27th, 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) ("EnWave" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), announced that Dairy Concepts
![EnWave Signs Technology and Evaluation License Option Agreement with Goldencrops Corporation, a Leading Southeast Asian Ingredient Company.](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
EnWave Signs Technology and Evaluation License Option Agreement with Goldencrops Corporation, a Leading Southeast Asian Ingredient Company.
Vancouver, B.C., May 3rd, 2022, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today
![EnWave unterzeichnet Technologie- und Evaluierungslizenz-Optionsvertrag mit Goldencrops Corporation, einem führenden südostasiatischen Ingredienzienhersteller](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
EnWave unterzeichnet Technologie- und Evaluierungslizenz-Optionsvertrag mit Goldencrops Corporation, einem führenden südostasiatischen Ingredienzienhersteller
Vancouver, B.C., 3. Mai 2022, EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab heute
![EnWave veranstaltet Showcase-Event mit Elea, um die Synergien der PEF- und REV™-Technologien hervorzuheben](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
EnWave veranstaltet Showcase-Event mit Elea, um die Synergien der PEF- und REV™-Technologien hervorzuheben
Vancouver, British Columbia, 13. April 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) („EnWave“ oder das „Unternehmen“ - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/)